<abstract xmlns="http://www.w3.org/1999/xhtml"><p>Hypomethylating agent decitabine is being used in the treatment of certain types of leukaemia in combination with other anticancer drugs. Aberrant DNA methylation has been suggested to occur in pathological states including depression. Scarce data in male rats suggest antidepressant effects of decitabine. The main aim of our studies is to test the hypothesis that the inhibition of DNA methylation results in antidepressant effects in female rats. Before doing so, we decided to verify the effects of decitabine on DNA methylation in females. The findings demonstrate that the treatment with decitabine at the dose shown previously to inhibit DNA methylation in males, had no effect on total DNA methylation in two brain regions, namely the hippocampus and frontal cortex of female rats. In conclusion, the present study allows us to suggest that the effect of decitabine on DNA methylation in the brain is sex dependent.</p></abstract>

Hypomethylating agent decitabine is being used in the treatment of certain types of leukaemia in combination with other anticancer drugs. Aberrant DNA methylation has been suggested to occur in pathological states including depression. Scarce data in male rats suggest antidepressant effects of decitabine. The main aim of our studies is to test the hypothesis that the inhibition of DNA methylation results in antidepressant effects in female rats. Before doing so, we decided to verify the effects of decitabine on DNA methylation in females. The findings demonstrate that the treatment with decitabine at the dose shown previously to inhibit DNA methylation in males, had no effect on total DNA methylation in two brain regions, namely the hippocampus and frontal cortex of female rats. In conclusion, the present study allows us to suggest that the effect of decitabine on DNA methylation in the brain is sex dependent.

Total DNA methylation in the brain in response to decitabine treatment in female rats

Biomedical Research Center, Institute of Experimental Endocrinology

Faculty of Pharmacy, Department of Pharmacology and Toxicology

European Pharmaceutical Journal

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Hypomethylating agent decitabine is being used in the treatment of certain types of leukaemia in combination with other anticancer drugs. Aberrant DNA...

Total DNA methylation in the brain in response to decitabine treatment in female rats

Pubblicato online: 26 dic 2019

Pagine: 1 - 3

Ricevuto: 18 mar 2019

Accettato: 30 mag 2019

DOI: https://doi.org/10.2478/afpuc-2019-0005

Parole chiave
5-aza-2′-deoxycytidine, epigenetics, gender

© 2019 L. Balagova et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Total DNA methylation in the brain in response to decitabine treatment in female rats

Pubblicato online: 26 dic 2019

Pagine: 1 - 3

Ricevuto: 18 mar 2019

Accettato: 30 mag 2019

DOI: https://doi.org/10.2478/afpuc-2019-0005

Parole chiave5-aza-2′-deoxycytidine, epigenetics, gender

© 2019 L. Balagova et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Parole chiave
5-aza-2′-deoxycytidine, epigenetics, gender